Ask AI
ProCE Banner Activity

MK-8591A-054: Interim Analysis of Safety and Efficacy of Reduced-Dose DOR/ISL in People Living With Virologically Suppressed HIV

Conference Coverage
Slideset

In the Week 48 interim analysis of the phase III MK-8591A-054 trial, people living with virologically suppressed HIV receiving DOL/ISL maintained virologic suppression after switching to a reduced dose, and total CD4+ cell and lymphocyte counts increased.

Released: October 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare